All In Biotech

Drug Trial Radar · NCT01133951

Helicobacter Pylori Eradication to Prevent Gastric Cancer

Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,000

Actual

Start

Jun 2010

Primary completion

Jan 2012

Study completion May 2032

Sponsor

Lead sponsor
Jie-Jun WangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 31, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 30 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection appears to reduce the risk of gastric cancer. However, several recent controlled interventional trials by H. pylori eradication to prevent gastric cancer have yielded disappointing results. The exact effect of H.pylori eradication on prevention of gastric cancer is unclear up to now. To clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether H pylori eradication would reduce the incidence of gastric cancer in a high-risk population in China.

Conditions

  • Helicobacter Infections
  • Stomach Neoplasms

Interventions

  • OAC triple therapyDrug

    Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.

  • PlaceboDrug

    Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Gastric cancer incidenceTime frame: 10 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhao-Lai Hua M.D.

    Yangzhong, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.